NV
KYTX icon

Northpond Ventures’s Kyverna Therapeutics KYTX Stock Holding History

Northpond Ventures’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$15.9M Hold
3,255,426
– – 36.46% 1
2024
Q2 		$24.4M Hold
3,255,426
– – 44.18% 1
2024
Q1 		$80.9M Buy
+3,255,426
New +$90.8M 78.8% 1

Other funds holding KYTX

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Northpond Ventures's KYTX Position: Q3 2024 in Review

Northpond Ventures held its Kyverna Therapeutics (KYTX) position steady in Q3 2024 at 3,255,426 shares worth $15.9M. The position accounts for 36.46% of the portfolio, ranked #1.

Northpond Ventures first reported a position in KYTX in Q1 2024 and has held it in 3 quarters since. The position peaked at $80.9M in Q1 2024. 94 funds tracked by Wall St. Rank hold KYTX as of Q3 2024.

  • Northpond Ventures held 3,255,426 shares of Kyverna Therapeutics worth $15.9M as of Q3 2024.
  • Northpond Ventures left its Kyverna Therapeutics share count unchanged in Q3 2024.
  • Kyverna Therapeutics made up 36.46% of Northpond Ventures's portfolio in Q3 2024, its #1 holding.
  • Northpond Ventures first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • Northpond Ventures's Kyverna Therapeutics position peaked at $80.9M in Q1 2024.
  • 94 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q3 2024.

Based on Northpond Ventures's 13F filing for Q3 2024, filed 14 Nov 2024.